MA.17R: Reduced Risk of Recurrence With Extending Adjuvant Letrozole Beyond 5 Yrs in Postmenopausal Women With Early-Stage Breast Cancer

This study conducted by the Canadian Cancer Trials Group is the first to show that extending aromatase inhibitor therapy beyond 5 years reduces the risk of disease recurrence.
Source: Clinical Care Options Breast Cancer - Category: Cancer & Oncology Source Type: research